Translational Development Acquisition (TDACW) Preferred Stock Liabilities (2024 - 2026)

Translational Development Acquisition (TDACW) has reported Preferred Stock Liabilities for 3 consecutive years, with $157.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Preferred Stock Liabilities fell 11.66% year-over-year to $157.3 million; the trailing twelve-month figure through Jun 2026 stood at $157.3 million (down 11.66% YoY), and the FY2025 full-year result was $181.7 million, up 4.19% from the prior year.
• Preferred Stock Liabilities fell to $157.3 million in Q2 2026 per TDACW's latest filing, from $183.3 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $183.3 million in Q1 2026 and bottomed at $157.3 million in Q2 2026.
• Historically, Preferred Stock Liabilities has averaged $175.8 million across 3 years, with a median of $178.0 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Preferred Stock Liabilities grew 4.19% in 2025, then slipped 11.66% in 2026.
• Over 3 years, Preferred Stock Liabilities stood at $174.4 million in 2024, then climbed by 4.19% to $181.7 million in 2025, then declined by 13.43% to $157.3 million in 2026.
• According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $157.3 million, $183.3 million, and $181.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.